METHOD FOR DETERMINING CLINICAL EFFECTIVENESS OF USING TAXANES FOR TREATING BREAST CANCER Russian patent published in 2025 - IPC C12Q1/68 

FIELD: medicine.

SUBSTANCE: invention relates to medicine. Disclosed is a method for determining clinical efficacy of using at least one taxane-containing preparation in treating breast cancer in a patient. Disclosed method includes the following steps: (a) expression levels of two groups of genes are measured in a patient’s tumour tissue sample: CASP8AP2, KIFC1, MCM5, NUP153, PRKD3, STMN1, SYNCRIP (group I) and CCND1, EIF4B, HMGCL, MAST4, MRPS30, NFATC4, OCEL1, SYBU (group II), wherein expression levels are measured using one of the following devices: a total RNA sequencing device, a microchip or a reverse transcription and polymerase chain reaction device; (b) calculating the value of the sum of the logarithms of the absolute levels of gene expression measured at step (a), wherein the expression levels of the group I genes are taken with a positive sign at the logarithm of the absolute expression level, the expression levels of the group II genes are taken with a negative sign at the logarithm of the absolute level of expression; (c) comparing the obtained value with a threshold value determined using said device for a group of patients with a known response status to therapy, and if the obtained threshold value is exceeded, the taxane-containing preparation is determined as a clinically effective agent for treating breast cancer in a patient.

EFFECT: proposed method enables to predict efficiency of response to preparations of taxane family, for example paclitaxel or docetaxel, for patients with breast cancer according to data obtained on different platforms of gene expression analysis.

7 cl, 10 dwg, 17 tbl, 4 ex